A biostatistician who has helped bring numerous lifesaving drugs to market is the recipient of the 2019 Lagakos Distinguished Alumni Award.
The award, given to Dr. Fong Wang Clow, senior vice president and head of biometrics and data management at Pharmacyclics, recognizes extraordinary achievements of graduates from Harvard T.H. Chan School of Public Health’s Department of Biostatistics.
Dr. John Quackenbush, Henry Pickering Walcott Professor of Computational Biology and Bioinformatics and chair of the Department of Biostatistics, presented the award at a ceremony on October 3 in a packed room at the Joseph B. Martin Conference Center.
During his opening remarks, Dr. Quackenbush discussed the spirit of the award, which honors the career of professor, Dr. Stephen Lagakos, who passed away in 2009. “Those of us who knew Steve realized that he was more than a brilliant scientist. His compassion, brilliance, and generosity made him special,” Dr. Quackenbush said. “Steven believed that the most important aspect of his career was training the next generation of scientists. He aspired to see students go on to achieve great things.”
To that end, Dr. Quackenbush noted that Dr. Clow’s list of accomplishments is as long as it is impactful. She played a key role in getting U.S. Food and Drug Administration (FDA) approval for eleven different cancer and graft versus host disease (GvHD) drug applications, as well as the only drug approved for treating stroke. She has never been turned down on a new drug application to the FDA in her 30-year career. “She’s had an impact on the lives of tens of thousands of individuals,” Dr. Quackenbush said.Friday Letter Submission, Publish on October 18